Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Special Issue "Novel Nanoparticle Formulations for Retinal Drug Delivery"
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".
Deadline for manuscript submissions: 31 August 2023 | Viewed by 971
Special Issue Editor
Interests: ophthalmology; neurodegeneration; neuroprotection; ex vivo retina cultures; drug delivery; retinal gene therapies; nanoparticle; small molecules therapies
Special Issue Information
The delivery of drugs intended to reach the retina is very complex. Nanocarriers, such as nanoparticles, can deliver ophthalmic drugs to specific targets and promise to revolutionise the treatment of many eye diseases. To date, the results strongly suggest that ophthalmology stands to benefit enormously from the use of this nanotechnology. In recent decades, nanotechnology appears to be creating new horizons for the treatment of ocular diseases by enabling the controlled release of drugs, ensuring fewer side effects, improving drug bioavailability, and forcing drug uptake into retinal cells. Numerous drug delivery systems have also been investigated regarding their ability to reach the posterior segment of the eye through topical application. The aim of this Special Issue is to provide an update on recent advancements in the synthesis, development and use of nanoparticles for drug delivery and sustained release in the retina, in view of the practical potential of nanoparticles and nanoformulations.
Dr. José Hurst
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- nano-based gene/drug delivery to target retinas/retinal explants/organoids
- targeted drug delivery to retinal cells
- formulation of nanoparticles for retinas
- organic and inorganic nanoparticles
- therapies for retinal diseases
- depot function of nanoparticles
- technologies for targeted delivery of DNA/RNA (ASO/nucleic acid)
- active transport/passive transport of nanoparticles